Literature DB >> 21878589

Long-term safety of radiotherapy and breast cancer laterality in older survivors.

Reina Haque1, Marianne Ulcickas Yood, Ann M Geiger, Aruna Kamineni, Chantal C Avila, Jiaxiao Shi, Rebecca A Silliman, Virginia P Quinn.   

Abstract

BACKGROUND: Although adjuvant radiotherapy (RT) following surgery for breast cancer improves overall survival, controversy exists about its long-term adverse impact on cardiovascular health in older survivors. AIM: To determine whether incident cardiovascular disease (CVD) is associated with RT and whether tumor laterality modifies this association.
METHODS: Women aged 65+ years diagnosed with stage I and II breast cancer between 1990 and 1994 were identified from three health plans. Women were followed through CVD outcomes, health plan disenrollment, death, or study end (December 31, 2004). The main independent variable was RT use. Adjusted HRs and 95% CIs were estimated using Cox proportional hazards models with time-dependent tamoxifen and RT use status. We adjusted for age, race, stage, estrogen receptor/progesterone receptor, hypertension, and diabetes.
RESULTS: In the full cohort (N = 806), RT was not associated with greater risk of CVD (maximum follow-up was 14 years). However, within the RT-exposed group (N = 340), women treated for left-side breast cancer had a significant increased risk of CVD outcomes (HR = 1.53, 95% CI: 1.06-2.21) compared with women with right-sided tumors.
CONCLUSION: Laterality is critical to understanding the effect of RT on CVD. Studies of more contemporary cohorts of women treated with RT should incorporate this variable to determine whether the risk persists with refinements in the dosing and delivery of RT. IMPACT: As some irradiation to the heart is unavoidable even with refined modern RT techniques, continued effort is required to minimize such exposures, especially in older women with left-sided tumors. ©2011 AACR

Entities:  

Mesh:

Year:  2011        PMID: 21878589      PMCID: PMC3784355          DOI: 10.1158/1055-9965.EPI-11-0348

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  29 in total

1.  Comparison of self-report, hospital discharge codes, and adjudication of cardiovascular events in the Women's Health Initiative.

Authors:  Susan R Heckbert; Charles Kooperberg; Monika M Safford; Bruce M Psaty; Judith Hsia; Anne McTiernan; J Michael Gaziano; William H Frishman; J David Curb
Journal:  Am J Epidemiol       Date:  2004-12-15       Impact factor: 4.897

Review 2.  Vascular damage as an underlying mechanism of cardiac and cerebral toxicity in irradiated cancer patients.

Authors:  F A Stewart; S Hoving; N S Russell
Journal:  Radiat Res       Date:  2010-08-30       Impact factor: 2.841

3.  Risk of cardiac death after adjuvant radiotherapy for breast cancer.

Authors:  Sharon H Giordano; Yong-Fang Kuo; Jean L Freeman; Thomas A Buchholz; Gabriel N Hortobagyi; James S Goodwin
Journal:  J Natl Cancer Inst       Date:  2005-03-16       Impact factor: 13.506

4.  Surveillance and ascertainment of cardiovascular events. The Cardiovascular Health Study.

Authors:  D G Ives; A L Fitzpatrick; D E Bild; B M Psaty; L H Kuller; P M Crowley; R G Cruise; S Theroux
Journal:  Ann Epidemiol       Date:  1995-07       Impact factor: 3.797

5.  Increased incidence of stroke in women with breast cancer.

Authors:  Greger Nilsson; Lars Holmberg; Hans Garmo; Andreas Terent; Carl Blomqvist
Journal:  Eur J Cancer       Date:  2005-02       Impact factor: 9.162

6.  A multicenter study of the coding accuracy of hospital discharge administrative data for patients admitted to cardiac care units in Ontario.

Authors:  Peter C Austin; Paul A Daly; Jack V Tu
Journal:  Am Heart J       Date:  2002-08       Impact factor: 4.749

7.  Mortality from myocardial infarction after adjuvant radiotherapy for breast cancer in the surveillance, epidemiology, and end-results cancer registries.

Authors:  L F Paszat; W J Mackillop; P A Groome; C Boyd; K Schulze; E Holowaty
Journal:  J Clin Oncol       Date:  1998-08       Impact factor: 44.544

8.  Cause-specific mortality in long-term survivors of breast cancer who participated in trials of radiotherapy.

Authors:  J Cuzick; H Stewart; L Rutqvist; J Houghton; R Edwards; C Redmond; R Peto; M Baum; B Fisher; H Host
Journal:  J Clin Oncol       Date:  1994-03       Impact factor: 44.544

9.  Mortality patterns over 34 years of breast cancer patients in a clinical trial of post-operative radiotherapy.

Authors:  J M Jones; G G Ribeiro
Journal:  Clin Radiol       Date:  1989-03       Impact factor: 2.350

Review 10.  Radiation-related heart disease: current knowledge and future prospects.

Authors:  Sarah C Darby; David J Cutter; Marjan Boerma; Louis S Constine; Luis F Fajardo; Kazunori Kodama; Kiyohiko Mabuchi; Lawrence B Marks; Fred A Mettler; Lori J Pierce; Klaus R Trott; Edward T H Yeh; Roy E Shore
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-03-01       Impact factor: 7.038

View more
  12 in total

Review 1.  Experimental radiation-induced heart disease: past, present, and future.

Authors:  Marjan Boerma
Journal:  Radiat Res       Date:  2012-06-04       Impact factor: 2.841

2.  Validation of electronic data on chemotherapy and hormone therapy use in HMOs.

Authors:  Debra P Ritzwoller; Nikki Carroll; Thomas Delate; Maureen O'Keeffe-Rossetti; Paul A Fishman; Elizabeth T Loggers; Erin J Aiello Bowles; Jennifer Elston-Lafata; Mark C Hornbrook
Journal:  Med Care       Date:  2013-10       Impact factor: 2.983

Review 3.  Cancer research network: using integrated healthcare delivery systems as platforms for cancer survivorship research.

Authors:  Larissa Nekhlyudov; Sarah M Greene; Jessica Chubak; Borsika Rabin; Leah Tuzzio; Sharon Rolnick; Terry S Field
Journal:  J Cancer Surviv       Date:  2012-12-14       Impact factor: 4.442

4.  Comprehensive evaluation of the incidence of late effects in 5-year survivors of breast cancer.

Authors:  Timothy L Lash; Soe Soe Thwin; Marianne Ulcickas Yood; Ann M Geiger; Jaclyn Bosco; Virginia P Quinn; Terry S Field; Pamala A Pawloski; Rebecca A Silliman
Journal:  Breast Cancer Res Treat       Date:  2014-03-01       Impact factor: 4.872

5.  Incident comorbidities and all-cause mortality among 5-year survivors of Stage I and II breast cancer diagnosed at age 65 or older: a prospective-matched cohort study.

Authors:  Jennifer H Jordan; Soe Soe Thwin; Timothy L Lash; Diana S M Buist; Terry S Field; Reina Haque; Pamala A Pawloski; Hans V Petersen; Marianne N Prout; Virginia P Quinn; Marianne Ulcickas Yood; Rebecca A Silliman; Ann M Geiger
Journal:  Breast Cancer Res Treat       Date:  2014-06-18       Impact factor: 4.872

6.  Comorbidities and cardiovascular disease risk in older breast cancer survivors.

Authors:  Reina Haque; Marianne Prout; Ann M Geiger; Aruna Kamineni; Soe Soe Thwin; Chantal Avila; Rebecca A Silliman; Virginia Quinn; Marianne Ulcickas Yood
Journal:  Am J Manag Care       Date:  2014       Impact factor: 2.229

7.  Genetic factors and breast cancer laterality.

Authors:  Magid H Amer
Journal:  Cancer Manag Res       Date:  2014-04-16       Impact factor: 3.989

8.  Biological dosimetry for breast cancer radiotherapy: a comparison of external beam and intraoperative radiotherapy.

Authors:  David K Woolf; Norman R Williams; Raheleh Bakshi; Seyed Yazdan Madani; David J Eaton; Sara Fawcitt; Katharine Pigott; Susan Short; Mohammed Keshtgar
Journal:  Springerplus       Date:  2014-06-30

Review 9.  Risk of death from cardiovascular disease following breast cancer: a systematic review.

Authors:  S A M Gernaat; P J Ho; N Rijnberg; M J Emaus; L M Baak; M Hartman; D E Grobbee; H M Verkooijen
Journal:  Breast Cancer Res Treat       Date:  2017-05-13       Impact factor: 4.872

10.  Cardiovascular disease risk and androgen deprivation therapy in patients with localised prostate cancer: a prospective cohort study.

Authors:  Reina Haque; Marianne UlcickasYood; Xiaoqing Xu; Andrea E Cassidy-Bushrow; Huei-Ting Tsai; Nancy L Keating; Stephen K Van Den Eeden; Arnold L Potosky
Journal:  Br J Cancer       Date:  2017-08-24       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.